Chang-Xin Shi

3.2k citations
20 papers · 1.7k indexed · 1 hit paper · h-index 17
Topics
Multiple Myeloma Research and Treatments (16 papers)Protein Degradation and Inhibitors (14 papers)Ubiquitin and proteasome pathways (6 papers)
Partner nations
United StatesCanadaChina

In The Last Decade

Chang-Xin Shi

20 papers receiving 1.6k citations

Hit Papers

Cereblon expression is required for the antimyeloma activ...20112026201620212011100200300400

Peers

Chang-Xin Shi
Comparison fields: 5 of 84
  • Molecular Biology 1.4k
  • Hematology 1.1k
  • Oncology 490
  • Pathology and Forensic Medicine 147
  • Cancer Research 131
Replace Laura A. Bruins with:
Laura A. Bruins United States
Victoria M. Garbitt United States
Christopher P. Wardell United Kingdom
Jessica Schmidt United States
Chad C. Bjorklund United States
Andrew R. Conery United States
Aniruddha J. Deshpande United States
Matthew C. Stubbs United States
Letha A. Phillips United States
Meredith J. Taylor United States
Chang-Xin Shi relative to Laura A. Bruins United States Laura A. Bruins's profile →
Citations per field
00.5×1.7×
Laura A. Bruins · 1×
Citations per year

Countries citing papers authored by Chang-Xin Shi

Since Specialization
Citations

This map shows the geographic impact of Chang-Xin Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chang-Xin Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chang-Xin Shi more than expected).

Fields of papers citing papers by Chang-Xin Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chang-Xin Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chang-Xin Shi. The network helps show where Chang-Xin Shi may publish in the future.

Co-authorship network of co-authors of Chang-Xin Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Chang-Xin Shi. A scholar is included among the top collaborators of Chang-Xin Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chang-Xin Shi. Chang-Xin Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 5
2 23
3 70
4 24
5 10
6 42
7 53
8 72
9 35
10 31
11 55
12 15
13 18
14 170
15 85
16 286
17 81
18
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomidebreakdown →
461
19 83
20 44

About Chang-Xin Shi

Chang-Xin Shi is a scholar working on Hematology, Molecular Biology and Oncology, having authored 20 papers that have together received 1.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (14 papers) and Ubiquitin and proteasome pathways (6 papers). The work is most often cited by research in Hematology (1.1k citations), Molecular Biology (1.4k citations) and Oncology (490 citations). Chang-Xin Shi has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Esteban Braggio, A. Keith Stewart, P. Leif Bergsagel, Jessica Schmidt, Laura A. Bruins, Rafaël Fonseca, Yuan Xiao Zhu, Xiu-Bao Chang, Scott Van Wier and Chad C. Bjorklund. Their work appears in journals such as Blood, PLoS ONE and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026